WHAT ARE PROTON PUMP INHIBITORS?
Proton Pump Inhibitors (PPI) were designed to reduce the amount of acid in the stomach. They are often used to prevent Gastroesophageal Reflux Disease (GERD) or heal inflammation of the esophagus. PPIs are amongst the most commonly prescribed drug in the United States. In 2009, they generated 13.9 Billion dollars and were the 3rd largest class of drug in the country.
Introduced by AstraZeneca in 1989. Over-the-counter was introduced in 2003.
Introduced by AstraZeneca in 2001. Over-the-counter was introduced in 2014.
Introduced by Pfizer in 2000.
Introduced by Takeda Pharmaceuticals in 1995. Over-the-counter was introduced in 2009.
Study finds association between duration of PPI use and increased risk of Chronic Kidney Disease (CKD).
Acute Kidney Injury
Chronic Kidney Disease
Acute Interstitial Nephritis
End-Stage Renal Disease
PPI LAWSUIT UPDATES
MDL 2789: August 2nd, 2017
Judge: Claire C. Cecchi
Venue: District of New Jersey
Pending Actions: 161
August 2nd, 2017
Plaintiff's motion to centralize was approved by the JPML, following the hearing in Los Angeles on July 27th, 2017. Significant developments, including pending actions filed, warranted the JPML taking a second look at centralization.
January 26th, 2017
Plaintiffs were denied their motion to centralize soon after this initial Judicial Panel on Multi-District Litigation (JPML) hearing in Miami.